Fibrosis and hypertensive heart disease

Current Opinion in Cardiology

Volumn 15, Issue 4, 2000, Pages 264-272

  Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOLE; CORONARY ARTERY; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; FIBROBLAST; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOMEGALY; CELL DIVISION; CORONARY VESSELS; ENDOMYOCARDIAL FIBROSIS; FIBROBLASTS; GROWTH INHIBITORS; GROWTH SUBSTANCES; HUMANS; HYPERTENSION; MODELS, CARDIOVASCULAR; MYOCARDIUM; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033916114     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200007000-00010     Document Type: Review

References (63)

1. 1 Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
2. 2 Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
3. 3 Shapiro LM, McKenna WJ: Left ventricular hypertrophy: relation of structure to diastolic function in hypertension. Br Heart J 1984, 51:637-642.
4. 4 Anderson KR, St. John Sutton MG, Lie JT: Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979, 128:79-85.
5. 5 Pearlman ES, Weber KT, Janicki JS, et al.: Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982, 46:158-164.
6. 6 Abrahams C, Janicki JS, Weber KT: Myocardial hypertrophy in Macaca fascicularis: structural remodeling of the collagen matrix. Lab Invest 1987, 56:676-683.
7. 7 Weber KT, Janicki JS, Shroff SG, et al.: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988, 62:757-765.
8. 8 Pick R, Janicki JS, Weber KT: Myocardial fibrosis in nonhuman primate with pressure overload hypertrophy. Am J Pathol 1989, 135:771-781.
9. 9 Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F: Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract 1989, 184:577-581.
10. 10 Frohlich ED, Apstein C, Chobanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 327:998-1008.
11. 11 Mulvany MJ: Vascular remodeling of resistance vessels: can we define this? Cardiovasc Res 1999, 41:9-13.
12. 12 Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998, 16:1031-1041.
13. 13 Diez J, Laviades C, Mayor G, et al.: Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995;91:1450-1456.
14. 14 Diez J, Panizo A, Gil MJ, et al.: Serum markers of collagen type I metabolism in spontaneously hypersensitive rats: relation to myocardial fibrosis. Circulation 1996;93:1026-1032.
15. 15 Laviades C, Varo N, Fernández J, et al.: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540.
16. 16 Querejeta R, Varo N, López B, et al.: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-1735.
17. 17 Schwartzkopff B, Strauer BE: Squeezing tubes - a case of remodeling and regulation. Coronary reserve in hypertensive heart disease. Cardiovasc Res 1998, 40:4-8.
18. 18 Susie D, Varagic J, Frohlich ED: Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens 1999, 17:1209-1215.
19. 19 Koren MJ, Devereux RB, Casale PN, et al.: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1990, 115:345-352.
20. 20 Cooper RS, Simmons BE, Castaner A, et al.: Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990, 65:441-445.
21. 21 Devereux RB, Roman MJ: Hypertensive left ventricular hypertrophy: pathogenesis, prognostic importance, and treatment. Cardiovasc Rev Rep 1992, 13(8):24-33.
22. 22 Weber KT: Hypertension: a case of the gratuitous rider. Cardiovasc Res 1996, 31:868-869.
23. 23 Weber KT: Hormones and fibrosis: a case for lost reciprocal regulation. News Physiol Sci 1994, 9:123-128.
24. 24 Weber KT: Angiotensin II and connective tissue: homeostasis and reciprocal regulation. Regul Pept 1999, 82:1-17.
25. 25 Weber KT: Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082.
26. 26 Emanueli C, Maestri R, Corradi D, et al.: Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999. 100:2359-2365.
27. 27 Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138-147.
28. 28 Sun Y, Zhang J, Zhang JQ, Ramires FJA: Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000, 35:1078-1084.
29. 29 Selye H: The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946, 6:117-230.
30. 30 Hall CE, Hall O: Hypertension and hypersalimentation. I. Aldosterone hypertension. Lab Invest 1965, 14:285-294.
31. 31 Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990, 67:1355-1364.
32. 32 Sun Y, Ratajska A, Zhou G, Weber KT: Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993, 122:395-403.
33. 33 Robert V, Van Thiem N, Cheav SL, et al.: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994, 24:30-36.
34. 34 Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
35. 35 Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269:E657-E662.
36. 36 Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
37. 37 Numaguchi K, Egashira K, Takemoto M, et al.: Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995, 26:957-962.
38. 38 Hou J, Kato H, Cohen RA, et al.: Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest 1995, 96:2469-2477.
39. 39 Takemoto M, Egashira K, Usui M, et al.: Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997, 99:278-287.
40. 40 Takemoto M, Egashira K, Tomita H, et al: Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade. Hypertension 1997, 30:1621-1627.
41. 41 Katoh M, Egashira K, Usui M, et al.: Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998, 83:743-751.
42. 42 Tomita H, Egashira K, Ohara Y, et al.: Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998, 32:273-279.
43. 43 Katoh M, Egashira K, Mitsui T, et al.: Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000, 32:73-83.
44. 44 Sun Y, Weber KT: Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 1996, 28:851-858.
45. 45 Azizi M, Rousseau A, Ezan E, et al.: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996, 97:839-844.
46. 46 Luvará G, Pueyo ME, Philippe M, et al.: Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall. Prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998, 18:1408-1416.
47. 47 Tomita H, Egashira K, Kubo-Inoue M, et al.: Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998, 18:1456-1464.
48. 48 Usui M, Egashira K, Tomita H, et al.: Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000, 101:305-310.
49. 49 Weber KT, Brilla CG, Campbell SE, et al.: Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992, 1:75-85.
50. 50 Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994, 23(Part 2):869-877.
51. 51 Jalil JE, Janicki JS, Pick R, Weber KT: Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens 1991, 4:51-55.
52. 52 Nicoletti A, Mandet C, Challah M, et al.: Mediators of perivascular inflammation in the left ventricle of renovascular hypertensive rats. Cardiovasc Res 1996, 31:585-595.
53. 53 McEwan PE, Gray GA, Sherry L, et al.: Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998, 98:2765-2773.
54. 54 Campbell SE, Janicki JS, Weber KT: Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995, 27:1545-1560.
55. 55 Katwa LC, Campbell SE, Tyagi SC, et al.: Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997, 29:1375-1386.
56. 56 Robert V, Heymes C, Silvestre J-S, et al.: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33:981-986.
57. 57 Kim S, Ohta K, Hamaguchi A, et al.: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994, 24:195-204.
58. 58 Everett AD, Tufro-McReddie A, Fisher A, Gomez RA: Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β expression. Hypertension 1994, 23:587-592.
59. 59 Tufro-McReddie A, Chevalier RL, Everett AD, Gomez RA: Decreased perfusion pressure modulates renin and ANG II type 1 receptor gene expression in the rat kidney. Am J Physiol 1993, 264:R696-R702.
60. 60 Freeman RH, Villarreal D, Vari RC, Verburg KM: Endogenous atrial natriuretic factor in dogs with caval constriction. Circ Res 1987, 61(Suppl 1):1-96-1-99.
61. 61 Davis JO: The physiology of congestive heart failure. In Handbook of Physiology vol. III (Circulation). Edited by Hamilton WF. Washington, DC: American Physiological Society; 1965:2071-2122.
62. 62 Brilla CG, Janicki JS, Weber KT: Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991, 69:107-115.
63. 63 Brilla CG, Matsubara L, Weber KT: Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996, 28:269-275.